First use of Bedaquiline, Linezolid, and Pretomanid (BPaL) in a family cluster of multi-drug resistant (MDR) TB infection.
作者信息
Pratt Marcus, McNicol Mark, Hunter Michael, Dedicoat Martin
机构信息
Department of Infectious Diseases, Belfast Health and Social Care Trust.
Department of Infectious Diseases, University Hospitals Birmingham NHS Trust.
出版信息
Ulster Med J. 2024 Dec;93(2):55-57. Epub 2024 Dec 11.
Abstract
摘要
相似文献
1
First use of Bedaquiline, Linezolid, and Pretomanid (BPaL) in a family cluster of multi-drug resistant (MDR) TB infection.
Ulster Med J. 2024 Dec;93(2):55-57. Epub 2024 Dec 11.
2
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
Clin Microbiol Infect. 2024 Sep;30(9):1197.e1-1197.e4. doi: 10.1016/j.cmi.2024.03.009. Epub 2024 Mar 13.
3
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
BMJ Open. 2021 Dec 3;11(12):e051521. doi: 10.1136/bmjopen-2021-051521.
4
A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides.
bioRxiv. 2024 Jun 11:2023.11.16.567434. doi: 10.1101/2023.11.16.567434.
5
The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
Clin Infect Dis. 2024 Mar 20;78(3):730-741. doi: 10.1093/cid/ciad653.
6
Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid.
PLOS Glob Public Health. 2023 Oct 18;3(10):e0002283. doi: 10.1371/journal.pgph.0002283. eCollection 2023.
7
The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)-Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings-A Prospective Cohort Study in Belarus and Uzbekistan.
Clin Infect Dis. 2025 Feb 18. doi: 10.1093/cid/ciaf035.
8
Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.00021-19. Print 2019 May.
9
Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.
Clin Infect Dis. 2023 Oct 5;77(7):1053-1062. doi: 10.1093/cid/ciad312.
10
Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.
BMJ Case Rep. 2021 Dec 7;14(12):e245612. doi: 10.1136/bcr-2021-245612.
本文引用的文献
1
Tackling Drug-Resistant Tuberculosis: New Challenges from the Old Pathogen .
Microorganisms. 2023 Sep 10;11(9):2277. doi: 10.3390/microorganisms11092277.
2
New advances in the treatments of drug-resistant tuberculosis.
Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(8):863-870. doi: 10.1080/14787210.2023.2240022. Epub 2023 Jul 25.
3
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: 10.1056/NEJMoa2117166.
4
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
N Engl J Med. 2022 Sep 1;387(9):810-823. doi: 10.1056/NEJMoa2119430.
5
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
N Engl J Med. 2020 Mar 5;382(10):893-902. doi: 10.1056/NEJMoa1901814.
6
Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.
Eur Respir J. 2017 Jul 27;50(1). doi: 10.1183/13993003.00061-2017. Print 2017 Jul.
7
PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.
Science. 2008 Nov 28;322(5906):1392-5. doi: 10.1126/science.1164571.
Zotero 插件